{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:08:34Z","timestamp":1786561714628,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","award":["Stategic investment fund"],"award-info":[{"award-number":["Stategic investment fund"]}],"id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008899","name":"University of South Carolina","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008899","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Xanthine oxidase inhibitors (XOis) are commonly used to treat gout and hyperuricemia. Beyond urate-lowering effects, XOis may influence cardiovascular outcomes via oxidative stress pathways. Prior evidence, including post hoc analyses of the CARES trial, suggests increased mortality after XOi discontinuation, raising concern for a potential \u201cwithdrawal syndrome.\u201d However, evidence from real-world outpatient populations is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to evaluate whether the recent discontinuation of XOi therapy is associated with an increased risk of acute cardiovascular events in patients with gout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the Merative MarketScan database. Adults with gout initiating allopurinol or febuxostat were included. Discontinuation was defined as no XOi supply in the prior 90\u00a0days during the 121- to 180-day window post-initiation. The primary outcome was hospitalization or outpatient diagnosis of acute myocardial infarction or ischemic stroke. Cox proportional hazards models with stabilized inverse probability weights were used to estimate hazard ratios (HRs), adjusting for demographic and clinical covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 508,872 patients initiating XOi therapy, 23.6% discontinued therapy within the first 121- to 180-day post-initiation timeframe. Discontinuers were younger with fewer comorbidities at baseline. After weighting, groups were well balanced. XOi discontinuation was associated with a modest but statistically significant increased risk of acute cardiovascular events (HR, 1.05; 95% CI, 1.01\u20131.09;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019). The magnitude of the effect increases among patients with preexisting hypertension diagnoses (HR, 1.13; 95% CI, 1.03\u20131.23;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large real-world cohort, early discontinuation of XOi therapy was linked to a small but significant elevation in cardiovascular risk. These findings support prior signals of potential harm from XOi withdrawal, particularly among patients with cardiovascular disease, and highlight the importance of sustained therapy adherence.<\/jats:p>\n                    <jats:p>\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td align=\"left\" colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>Xanthine oxidase inhibitor (XOi) discontinuation was associated with a modest but significant increase in acute cardiovascular events in a large national cohort of patients with gout.<\/jats:italic>\n                                \u2022\n                                <jats:italic>Even early discontinuation after XOi initiation may increase cardiovascular risk, underscoring the importance of treatment persistence.<\/jats:italic>\n                                \u2022\n                                <jats:italic>Adherence to XOi therapy may be an important factor in reducing cardiovascular risk among gout patients.<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-025-07899-7","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T05:42:35Z","timestamp":1766727755000},"page":"1431-1438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-0097","authenticated-orcid":false,"given":"Joseph","family":"Magagnoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy H.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Scott","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakrishna","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"6","key":"7899_CR1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM et al (2020) 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken) 72(6):744\u2013760","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"22","key":"7899_CR2","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1161\/01.cir.0000017502.58595.ed","volume":"105","author":"W Doehner","year":"2002","unstructured":"Doehner W, Schoene N, Rauchhaus M et al (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105(22):2619\u20132624. https:\/\/doi.org\/10.1161\/01.cir.0000017502.58595.ed","journal-title":"Circulation"},{"issue":"8","key":"7899_CR3","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jacc.2010.12.052","volume":"58","author":"NS Rajendra","year":"2011","unstructured":"Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, Struthers AD (2011) Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 58(8):820\u2013828. https:\/\/doi.org\/10.1016\/j.jacc.2010.12.052","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"7899_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1161\/01.cir.0000022140.61460.1d","volume":"106","author":"CA Farquharson","year":"2002","unstructured":"Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD (2002) Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106(2):221\u2013226. https:\/\/doi.org\/10.1161\/01.cir.0000022140.61460.1d","journal-title":"Circulation"},{"issue":"13","key":"7899_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378(13):1200\u20131210. https:\/\/doi.org\/10.1056\/NEJMoa1710895","journal-title":"N Engl J Med"},{"issue":"8","key":"7899_CR6","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/art.40914","volume":"71","author":"MR Bubb","year":"2019","unstructured":"Bubb MR (2019) Excess deaths upon cessation of xanthine oxidase inhibitor treatment-data from the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial: comment on the article by Choi et al. Arthritis Rheumatol 71(8):1391\u20131392. https:\/\/doi.org\/10.1002\/art.40914","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"7899_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-00194","volume":"8","author":"BZ Ghang","year":"2022","unstructured":"Ghang BZ, Lee JS, Choi J, Kim J, Yoo B (2022) Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open 8(2):e001944. https:\/\/doi.org\/10.1136\/rmdopen-2021-00194","journal-title":"RMD Open"},{"issue":"11","key":"7899_CR8","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/art.41066","volume":"71","author":"TA Johnson","year":"2019","unstructured":"Johnson TA, Kamatani N, Kuwabara M (2019) Xanthine oxidase inhibitor withdrawal syndrome? Comment on the article by Choi et al. Arthritis Rheumatol 71(11):1966\u20131967. https:\/\/doi.org\/10.1002\/art.41066","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"7899_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/15257770802138558","volume":"27","author":"YY Sautin","year":"2008","unstructured":"Sautin YY, Johnson RJ (2008) Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 27(6):608\u2013619. https:\/\/doi.org\/10.1080\/15257770802138558","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"7899_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","volume":"18","author":"M Bredemeier","year":"2018","unstructured":"Bredemeier M, Lopes LM, Eisenreich MA et al (2018) Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 18:24. https:\/\/doi.org\/10.1186\/s12872-018-0757-9","journal-title":"BMC Cardiovasc Disord"},{"key":"7899_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1289386","volume":"14","author":"M Kuwabara","year":"2024","unstructured":"Kuwabara M, Nakai M, Sumita Y et al (2024) Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome. Front Pharmacol 14:1289386. https:\/\/doi.org\/10.3389\/fphar.2023.1289386","journal-title":"Front Pharmacol"},{"issue":"Suppl 3","key":"7899_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/annrheumdis-2012-eular.2852","volume":"71","author":"P Richette","year":"2012","unstructured":"Richette P, Flipo R-M, Errieau G, Perrissin L, Clerson P (2012) Five phenotype profiles are revealed by cluster analysis in patients with gout: results from a cohort of 2762 patients. Ann Rheum Dis 71(Suppl 3):448. https:\/\/doi.org\/10.1136\/annrheumdis-2012-eular.2852","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7899_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","volume":"74","author":"P Richette","year":"2015","unstructured":"Richette P, Clerson P, P\u00e9rissin L, Flipo RM, Bardin T (2015) Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis 74(1):142\u2013147. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203779","journal-title":"Ann Rheum Dis"},{"key":"7899_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","volume":"269","author":"GJ Mart\u00ednez","year":"2018","unstructured":"Mart\u00ednez GJ, Celermajer DS, Patel S (2018) The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 269:262\u2013271. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.12.027","journal-title":"Atherosclerosis"},{"issue":"3","key":"7899_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2337\/dc23-1825","volume":"47","author":"F Roubille","year":"2024","unstructured":"Roubille F, Bouabdallaoui N, Kouz S et al (2024) Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). Diabetes Care 47(3):467\u2013470. https:\/\/doi.org\/10.2337\/dc23-1825","journal-title":"Diabetes Care"},{"issue":"42","key":"7899_CR16","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa65","volume":"41","author":"N Bouabdallaoui","year":"2020","unstructured":"Bouabdallaoui N, Tardif JC, Waters DD et al (2020) Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). Eur Heart J 41(42):4092\u20134099. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa65","journal-title":"Eur Heart J"},{"issue":"6","key":"7899_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/CRD.0000000000000650","volume":"33","author":"P Gera","year":"2025","unstructured":"Gera P, Wasserstein DH, Frishman WH, Aronow WS (2025) Low-dose colchicine for the prevention of cardiovascular events after acute coronary syndrome. Cardiol Rev 33(6):517\u2013521. https:\/\/doi.org\/10.1097\/CRD.0000000000000650","journal-title":"Cardiol Rev"},{"issue":"10","key":"7899_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22336","volume":"66","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V (2014) Medication adherence in gout: a systematic review. Arthritis Care Res 66(10):1551\u20131559","journal-title":"Arthritis Care Res"},{"issue":"3","key":"7899_CR19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10067-014-2823-8","volume":"35","author":"B McGowan","year":"2016","unstructured":"McGowan B, Bennett K, Silke C, Whelan B (2016) Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol 35(3):715\u2013721","journal-title":"Clin Rheumatol"},{"key":"7899_CR20","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3899\/jrheum.220270","volume":"49","author":"GB Coleman","year":"2022","unstructured":"Coleman GB, Dalbeth N, Frampton C et al (2022) Long-term follow-up of a randomized controlled trial of allopurinol dose escalation to achieve target serum urate in people with gout. J Rheumatol 49:1372\u20131378","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07899-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07899-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07899-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:02:43Z","timestamp":1769763763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07899-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7899"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07899-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used de-identified administrative claims data and did not involve direct patient contact or the collection of identifiable personal information. In accordance with 45 CFR \u00a746.104(d)(4), it was exempt from institutional review board (IRB) review and the requirement for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sutton has received research grants from Boehringer Ingelheim, Coherus BioSciences, EMD Serono, Gilead, and Alexion Pharmaceuticals, all for projects unrelated to the study. Jayakrishna Ambati is a co-founder of iVeena Holdings, iVeena Delivery Systems, and Inflammasome Therapeutics. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work, the authors used ChatGPT to improve the readability and language of the manuscript. After using this tool\/service, the authors reviewed and edited the content as needed and took full responsibility for the content of the published article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}]}}